The pharmaceutical industry is undergoing a structural shift where ESG considerations are no longer peripheral but central to growth strategies. Increasing regulatory pressure, investor scrutiny, and stakeholder expectations are compelling companies to embed sustainability into core operations. In 2025, over 70% of global pharmaceutical firms reported enhanced ESG disclosures, reflecting a broader move toward transparency and accountability. Environmental concerns such as car